glyburide has been researched along with Neoplasms in 14 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with glibenclamide could be associated with higher mortality for cardiovascular diseases and malignancies, in comparison with gliclazide." | 3.74 | Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. ( Balzi, D; Barchielli, A; Buiatti, E; Lamanna, C; Mannucci, E; Marchionni, N; Masotti, G; Monami, M, 2007) |
| "Metformin, a first-line medication for type 2 diabetes mellitus, arouses growing concerns on its anti-cancer effect." | 2.55 | Enemies or weapons in hands: investigational anti-diabetic drug glibenclamide and cancer risk. ( Gao, R; Xu, W; Yang, T, 2017) |
| "It is pivotal and remains challenge for cancer precision treatment to identify the survival outcome interactions between genes, cells and drugs." | 1.62 | siGCD: a web server to explore survival interaction of genes, cells and drugs in human cancers. ( Cui, X; Han, L; Li, Y; Liu, Y; Song, B; Sun, W; Wang, H; Zhang, Y; Zhou, W, 2021) |
| " In secondary analyses, duration- and dose-response relationships were observed, with longer cumulative durations and cumulative doses associated with an increased risk of any cancer (>36 months: HR 1." | 1.42 | The Use of Glyburide Compared With Other Sulfonylureas and the Risk of Cancer in Patients With Type 2 Diabetes. ( Azoulay, L; Majdan, A; Tuccori, M; Wu, JW; Yin, H, 2015) |
| "Hyperglycaemia is a risk factor for cancer and some sulphonylureas have anti-oxidant properties." | 1.36 | Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. ( Chan, JC; Chow, CC; Ko, GT; Kong, AP; Luk, AO; Ma, RC; Ng, VW; Ozaki, R; So, WY; Tong, PC; Yang, X; Yu, LW, 2010) |
| " At the same time about 1/3 of these serious adverse drug reactions (ADR) was found to have been reported to the ADR-register." | 1.27 | Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden. ( Westerholm, B; Wiholm, BE, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 2 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 2 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Zhou, Y | 1 |
| Song, M | 1 |
| Xie, D | 1 |
| Yan, S | 1 |
| Yu, S | 1 |
| Xie, S | 1 |
| Cai, M | 1 |
| Li, H | 1 |
| Shang, L | 1 |
| Yuan, C | 1 |
| Huang, M | 1 |
| Li, J | 1 |
| Xu, P | 1 |
| Cui, X | 1 |
| Han, L | 1 |
| Liu, Y | 1 |
| Sun, W | 1 |
| Song, B | 1 |
| Zhou, W | 1 |
| Zhang, Y | 1 |
| Wang, H | 1 |
| Gao, R | 1 |
| Yang, T | 1 |
| Xu, W | 1 |
| Tokunaga, T | 1 |
| Ando, T | 1 |
| Suzuki-Karasaki, M | 1 |
| Ito, T | 1 |
| Onoe-Takahashi, A | 1 |
| Ochiai, T | 1 |
| Soma, M | 1 |
| Suzuki-Karasaki, Y | 1 |
| Bo, S | 1 |
| Castiglione, A | 1 |
| Ghigo, E | 1 |
| Gentile, L | 1 |
| Durazzo, M | 1 |
| Cavallo-Perin, P | 1 |
| Ciccone, G | 1 |
| Lamos, EL | 1 |
| Stein, SA | 1 |
| Davis, SN | 1 |
| Tuccori, M | 1 |
| Wu, JW | 1 |
| Yin, H | 1 |
| Majdan, A | 1 |
| Azoulay, L | 1 |
| Monami, M | 2 |
| Lamanna, C | 2 |
| Balzi, D | 2 |
| Marchionni, N | 2 |
| Mannucci, E | 2 |
| Yang, X | 1 |
| So, WY | 1 |
| Ma, RC | 1 |
| Yu, LW | 1 |
| Ko, GT | 1 |
| Kong, AP | 1 |
| Ng, VW | 1 |
| Luk, AO | 1 |
| Ozaki, R | 1 |
| Tong, PC | 1 |
| Chow, CC | 1 |
| Chan, JC | 1 |
| Barchielli, A | 1 |
| Masotti, G | 1 |
| Buiatti, E | 1 |
| Han, X | 1 |
| Wang, F | 1 |
| Yao, W | 1 |
| Xing, H | 1 |
| Weng, D | 1 |
| Song, X | 1 |
| Chen, G | 1 |
| Xi, L | 1 |
| Zhu, T | 1 |
| Zhou, J | 1 |
| Xu, G | 1 |
| Wang, S | 1 |
| Meng, L | 1 |
| Iadecola, C | 1 |
| Wang, G | 1 |
| Ma, D | 1 |
| Wiholm, BE | 1 |
| Westerholm, B | 1 |
3 reviews available for glyburide and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Enemies or weapons in hands: investigational anti-diabetic drug glibenclamide and cancer risk.
Topics: Animals; ATP-Binding Cassette Transporters; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycem | 2017 |
Sulfonylureas and meglitinides: historical and contemporary issues.
Topics: Animals; Benzamides; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Glyburide; History, 20th | 2013 |
11 other studies available for glyburide and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Structural Dynamics-Driven Discovery of Anticancer and Antimetastatic Effects of Diltiazem and Glibenclamide Targeting Urokinase Receptor.
Topics: Diltiazem; Glyburide; Humans; Ligands; Neoplasms; Urokinase-Type Plasminogen Activator | 2023 |
siGCD: a web server to explore survival interaction of genes, cells and drugs in human cancers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Synergism; ErbB Receptors; Gene Expression Regulation | 2021 |
Plasma-stimulated medium kills TRAIL-resistant human malignant cells by promoting caspase-independent cell death via membrane potential and calcium dynamics modulation.
Topics: Calcium; Caspase 3; Caspase 7; Cell Death; Cell Line, Tumor; Culture Media; Dose-Response Relationsh | 2018 |
Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Topics: Adult; Aged; Cardiovascular Diseases; Cause of Death; Cohort Studies; Confounding Factors, Epidemiol | 2013 |
The Use of Glyburide Compared With Other Sulfonylureas and the Risk of Cancer in Patients With Type 2 Diabetes.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Mal | 2015 |
Sulphonylureas and cancer: a case-control study.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Gliclazide; Glybur | 2009 |
Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry.
Topics: Aged; Asian People; Cohort Studies; Diabetes Mellitus, Type 2; Female; Gliclazide; Glipizide; Glybur | 2010 |
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; | 2007 |
Heat shock proteins and p53 play a critical role in K+ channel-mediated tumor cell proliferation and apoptosis.
Topics: 4-Aminopyridine; Alkaloids; Apoptosis; bcl-2-Associated X Protein; Benzylisoquinolines; Calcium Chan | 2007 |
Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden.
Topics: Acidosis; Aged; Anti-Infective Agents, Urinary; Biguanides; Congenital Abnormalities; Contraceptives | 1984 |